Hepatic phase I and phase II biotransformations in quail and trout: comparison to other species commonly used in toxicity testing |
| |
Authors: | Z Gregus J B Watkins T N Thompson M J Harvey K Rozman C D Klaassen |
| |
Affiliation: | 1. Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66103 USA;2. Gesellschaft fur Strahlen -und Umweltforschung, mbH Munchen 8042 Neuherberg, Federal Republic of Germany |
| |
Abstract: | The ability of quail and trout to perform a number of representative phase I and phase II biotransformations was examined. To facilitate interspecies comparisons, metabolism of the same substrates was examined simultaneously under uniform conditions for rat, mouse, rabbit, guinea pig, cat, and dog. Both nonmammalian species can metabolize four representative substrates of phase I mixed-function oxidases and one substrate of epoxide hydrolase, though activity tended to be lower than that of the mammals. Important differences in the conjugative pathways were also noted. Among these differences were the quail's relative deficiency in glutathione conjugation and the trout's low ability to conjugate sulfate compounds. Trout liver UDP-glucuronosyltransferase activity was remarkably high toward testosterone and bilirubin, while quail liver formed glucuronides of naphthol, p-nitrophenol, and digitoxigenin-monodigitoxoside. Also noteworthy was the high N-acetyltransferase activity of both quail and trout toward isoniazid, beta-naphthylamine, and 2-aminofluorene. Differences in substrate specificity for a given enzymatic pathway may be an indication that multiple forms of drug metabolizing systems also occur in these nonmammalian species. Observation of several hundred- or even thousand-fold differences between species in their enzyme activities for certain substrates under uniform conditions re-emphasizes the need for caution in extrapolation of xenobiotic metabolism from one species to another. |
| |
Keywords: | Address all correspondence to Curtis D. Klaassen Ph.D. Department of Pharmacology Toxicology and Therapeutics University of Kansas Medical Center Kansas City KS 66103. |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|